Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Clinically Ill Older Adults at High Risk of Death or Severe Disability - Supplement
针对死亡或严重残疾高风险的临床疾病老年人的专业姑息治疗与重症监护相结合的随机试验 - 补充
基本信息
- 批准号:10714105
- 负责人:
- 金额:$ 39.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcademyAcuteAdministrative SupplementAlzheimer&aposs disease patientAlzheimer&aposs disease related dementiaAreaCaregiver supportCaregiversCaringCommunicationComplexCritical CareCritical IllnessDataElderlyEnhancement TechnologyFamilyFamily CaregiverGoalsGroup ProcessesHealthHospitalizationHospitalsInterventionLightMedicineMethodsOutcomePalliative CareParentsPatient CarePatient PreferencesPatient-Centered CarePatientsPhysiciansProviderQuality of CareResearch PersonnelSignal TransductionSpecialistTechnologyTraining ProgramsTreatment EfficacyWorkarmclinical caredisabilityefficacy evaluationend of lifeevidence basefunctional declinehigh riskhospital readmissionimprovedinnovationmedical specialtiesmortality riskolder patientpatient engagementpilot trialprogramsrandomized trialskill acquisitionskillsusability
项目摘要
ABSTRACT
The National Academy of Medicine has identified improving clinicians’ serious illness
communication skills (SICS) as a priority area to improve patient and family outcomes near the end
of life. SICS are particularly important for hospitalized patients with moderate-to-severe Alzheimer’s
disease or related dementias (ADRD) because: 1) patients’ preferences vary substantially regarding
goals of care in this context; and 2) hospitalization often signals a worsening health trajectory with
cascading readmissions and functional decline, and therefore presents an opportunity to engage in
robust goals of care conversations. However, a critical barrier to achieving widespread
improvements in this aspect of care for hospitalized ADRD patients is the absence of a scalable,
empirically-validated way to help clinicians acquire the complex communication skills needed to
engage patients and families in goals of care discussions in the hospital setting.
The parent R01 on which this supplement builds is an RCT among critically ill older patients
assessing the efficacy of an intervention involving goals-of-care conversations delivered by palliative
care (PC) specialists to improve patient and family caregiver outcomes. The broad focus of both the
parent R01 and this ADRD supplement is on caregiver support and patient-centered care through
enhanced clinician-patient-caregiver communication. In light of the workforce shortages for PC
specialists, improving the skills of non-PC specialists, which is the goal of the supplement proposal,
is a critical strategy to increase care quality for hospitalized ADRD patients.
Our goal is to create and disseminate a technology-enhanced intervention that is both
scalable and empirically-validated to help hospital-based physicians and advanced practice
providers (APPs) acquire the skills needed to effectively conduct goals-of-care conversations for
hospitalized patients with ADRD and their families. Therefore, in Aim 1, we will use a nominal group
process to engage a diverse stakeholder panel in the construction of the technology-enhanced SICS
intervention for clinicians treating patients with ADRD. In Aim 2, we will conduct a single-arm pilot
trial to evaluate the feasibility, acceptability, and efficacy (i.e., skills acquisition) of the SICS
intervention.
The proposed work will have high impact because it will yield the preliminary data needed
for a successful R01 application to conduct an RCT to determine the impact of the scalable SICS
intervention on the outcomes of hospitalized patients with ADRD and their caregivers. The project is
innovative because it seeks to develop the first empirically-validated SICS intervention for clinicians
of patients with ADRD that leverages technology to achieve high scalability. The work is feasible in
our hands because we are a team of established investigators with a strong commitment to
improving patient and caregiver outcomes in ADRD.
抽象的
美国国家医学院已确定“改善”严重疾病
沟通技巧(SICS)作为接近尾声改善患者和家庭结果的优先领域
SICS 对于患有中度至重度阿尔茨海默病的住院患者尤其重要。
疾病或相关痴呆症 (ADRD),因为:1) 患者对于以下方面的偏好差异很大:
在此背景下的护理目标;2) 住院通常预示着健康状况恶化
级联再入院和功能衰退,因此提供了参与的机会
然而,实现广泛的护理对话的一个关键障碍。
对住院 ADRD 患者的护理在这方面的改进是缺乏可扩展的、
经过经验验证的方法,可帮助您获得所需的复杂沟通技能
让患者和家属参与医院环境中的护理讨论目标。
该补充剂所基于的母版 R01 是一项针对老年危重患者的随机对照试验
评估涉及姑息治疗提供的护理目标对话的干预措施的有效性
护理(PC)专家改善患者和家庭护理人员的结果是双方的广泛关注点。
父母 R01 和此 ADRD 补充剂通过以下方式提供护理人员支持和以患者为中心的护理
鉴于 PC 劳动力短缺,加强了临床医生、患者和护理人员之间的沟通。
专家,提高非 PC 专家的技能,这是补充提案的目标,
是提高住院 ADRD 患者护理质量的关键策略。
我们的目标是创建并传播一种技术增强的干预措施,
可扩展且经过经验验证,可帮助医院医生和先进实践
提供者(APP)获得有效开展护理目标对话所需的技能
因此,在目标 1 中,我们将使用名义组。
让多元化利益相关者小组参与技术增强型 SICS 建设的流程
在目标 2 中,我们将进行单臂试点。
评估 SICS 的可行性、可接受性和有效性(即技能获取)的试验
干涉。
拟议的工作将产生重大影响,因为它将产生所需的初步数据
为成功的 R01 应用程序进行 RCT 以确定可扩展 SICS 的影响
对住院 ADRD 患者及其护理人员的结果进行干预 该项目是。
创新是因为它旨在为居民开发第一个经过经验验证的 SICS 干预措施
ADRD 患者利用技术实现高可扩展性这项工作是可行的。
我们的双手,因为我们是一支由成熟的调查人员组成的团队,坚定地致力于
改善 ADRD 患者和护理人员的治疗效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yael Schenker其他文献
Yael Schenker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yael Schenker', 18)}}的其他基金
Midcareer Investigator Award in Patient-Oriented Research: Yael Schenker, MD, MAS
以患者为导向的研究中的职业生涯中期研究员奖:Yael Schenker,医学博士,MAS
- 批准号:
10592288 - 财政年份:2021
- 资助金额:
$ 39.45万 - 项目类别:
Midcareer Investigator Award in Patient-Oriented Research: Yael Schenker, MD, MAS
以患者为导向的研究中的职业生涯中期研究员奖:Yael Schenker,医学博士,MAS
- 批准号:
10390440 - 财政年份:2021
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10437935 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10256820 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10663861 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Randomized Trial of Specialty Palliative Care Integrated with Critical Care for Critically Ill Older Adults at High Risk of Death or Severe Disability
针对死亡或严重残疾风险高的危重老年人的专业姑息治疗与重症监护相结合的随机试验
- 批准号:
10030184 - 财政年份:2020
- 资助金额:
$ 39.45万 - 项目类别:
Patient-centered and efficacious advance care planning in cancer: the PEACe comparative effectiveness trial
以患者为中心且有效的癌症预先护理计划:PEACe 比较有效性试验
- 批准号:
10401346 - 财政年份:2019
- 资助金额:
$ 39.45万 - 项目类别:
Patient-centered and efficacious advance care planning in cancer: the PEACe comparative effectiveness trial
以患者为中心且有效的癌症预先护理计划:PEACe 比较有效性试验
- 批准号:
10569584 - 财政年份:2019
- 资助金额:
$ 39.45万 - 项目类别:
A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer
针对晚期癌症患者进行初级姑息治疗干预 (CONNECT) 的整群随机试验
- 批准号:
9103638 - 财政年份:2016
- 资助金额:
$ 39.45万 - 项目类别:
A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer
针对晚期癌症患者进行初级姑息治疗干预 (CONNECT) 的整群随机试验
- 批准号:
9268708 - 财政年份:2016
- 资助金额:
$ 39.45万 - 项目类别:
相似国自然基金
巨噬细胞Nogo-B通过FABP4/IL-18/IL-18R调控急性肝衰竭的分子机制研究
- 批准号:82304503
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
α7nAChR激动剂通过PGC-1α和HO-1调控肾小管上皮细胞线粒体的质和量进而改善脓毒症急性肾损伤的机制研究
- 批准号:82372172
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于解郁散热“把好气分关”探讨代谢-炎症“开关”A2BR在急性胰腺炎既病防变中的作用与机制
- 批准号:82374256
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
RacGAP1介导细胞核-线粒体对话在急性肾损伤中促进肾小管上皮细胞能量平衡的作用机制研究
- 批准号:82300771
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
开窍寒温配伍调控应激颗粒铁离子富集水平抗急性缺血性卒中铁死亡损伤的机制研究
- 批准号:82374209
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
I-TRANSFER Improving TRansitions ANd outcomeS oF sEpsis suRvivors
I-TRANSFER 改善脓毒症幸存者的转变和结果
- 批准号:
10824878 - 财政年份:2023
- 资助金额:
$ 39.45万 - 项目类别:
Developing a culturally adapted implementation program for teleophthalmology use in Latinx communities
制定适合拉丁裔社区远程眼科使用的文化适应实施计划
- 批准号:
10771837 - 财政年份:2023
- 资助金额:
$ 39.45万 - 项目类别:
Mentored research in the intersection of kidney and cardiovascular disease
肾脏和心血管疾病交叉领域的指导研究
- 批准号:
10795588 - 财政年份:2023
- 资助金额:
$ 39.45万 - 项目类别:
Practical Approaches to Care in Emergency Syncope (PACES)
紧急晕厥的实用护理方法 (PACES)
- 批准号:
10854193 - 财政年份:2023
- 资助金额:
$ 39.45万 - 项目类别: